Loading...
Docoh

Taro Pharmaceutical Industries (TARO)

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

TARO stock data

Calendar

25 Jul 22
13 Aug 22
31 Mar 23
Quarter (USD) Mar 22 Mar 21 Mar 20 Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Mar 22 Mar 21 Mar 20 Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
2.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 67 70 -4.3%
Opened positions 7 8 -12.5%
Closed positions 10 7 +42.9%
Increased positions 22 18 +22.2%
Reduced positions 27 30 -10.0%
13F shares Current Prev Q Change
Total value 198.49M 655.91M -69.7%
Total shares 4.48M 4.62M -2.9%
Total puts 1K 0 NEW
Total calls 400 0 NEW
Total put/call ratio 2.5
Largest owners Shares Value Change
Renaissance Technologies 678.3K $29.34M -2.5%
Krensavage Asset Management 565.95K $24.48M +5.0%
Dimensional Fund Advisors 534.63K $23.13M +3.5%
Brandes Investment Partners 379.32K $16.41M +8.5%
Acadian Asset Management 326.43K $14.09M -4.1%
FMR 320.06K $13.85M -28.1%
IVZ Invesco 231.5K $10.01M -15.7%
AMP Ameriprise Financial 222.84K $9.64M +47.2%
Eversept Partners 220.29K $9.53M +21.6%
Hotchkis & Wiley Capital Management 191.82K $8.3M +22.2%
Largest transactions Shares Bought/sold Change
FMR 320.06K -125.22K -28.1%
AMP Ameriprise Financial 222.84K +71.49K +47.2%
Norges Bank 0 -60.79K EXIT
NTRS Northern Trust 20.94K -51.34K -71.0%
IVZ Invesco 231.5K -43.16K -15.7%
Eversept Partners 220.29K +39.14K +21.6%
Hotchkis & Wiley Capital Management 191.82K +34.8K +22.2%
Brandes Investment Partners 379.32K +29.61K +8.5%
Krensavage Asset Management 565.95K +26.98K +5.0%
Dimensional Fund Advisors 534.63K +17.95K +3.5%

Financial report summary

?
Competition
AkornTeligent

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: acne, adulterated, Alchemee, anti, argued, assembled, attrition, authoritative, beautify, Biden, bifurcated, Bill, Bowne, CAL, card, chair, Chapter, CIT, clause, Clawback, cleanse, clearance, conclusion, condensed, Congressional, contempt, contrary, Coote, CSA, defective, Delaware, Differin, DPP, eager, endeavor, entirety, EPS, fact, faster, fifty, freestanding, FTC, gas, geopolitical, GRASE, greenhouse, heighten, Herzlya, host, inactive, inconsistency, inconsistent, indemnity, inferior, influential, injured, insufficient, intensification, Interbank, Japan, Kingdom, KK, layer, LLC, logistic, London, lost, Lynch, macroeconomic, magazine, MEEM, merchandise, merchant, Merrill, Mifalot, Minister, misbranded, MONETA, monograph, NADAC, necessitate, neoplastic, oassessing, odetermining, orecommending, override, Oxymetazoline, parallel, persuade, plaintiff, pose, posture, preemption, premarket, Proactiv, Proactive, ProactivMD, proceed, profession, proper, provisional, Prudential, quickly, randomized, Realty, recapture, recession, Reichman, rulemaking, Russia, Safer, shortage, skincare, slowdown, stolen, Sulfate, sunscreen, Suprep, survey, tangible, Task, Template, text, Today, TPC, transparency, transparent, trapped, Treasurer, Ukraine, unfair, unlawful, unsafe, unusable, unwilling, vaccinated, Vicept, voluntarily, wage, waive, war, William, yield, YK
Removed: aa, advertise, advertised, advocacy, Analytical, API, Attestation, Avi, Avramoff, cancellation, cancelled, competence, consolidating, decide, feedback, FX, geographical, Herzliya, IDC, Imiquimod, instruct, Interdisciplinary, Itamar, Ivermectin, Karsenti, LLP, Magistrate, MBA, Michele, Micro, obligated, OSD, penned, Pertinent, Pharmacokinetic, Pharmacovigilance, preclude, preference, Princeton, progressively, promoted, QUANTITATIVE, ratified, reconsidered, recoverability, repeal, Secretary, Stern, Sulf, TDC, terminate, TIMETABLE, UNRESOLVED, Visosky, worked
Proxies
No filings

Patents

Utility
Stable Topical Compositions of Fenoldopam
10 Feb 22
The present disclosure is directed to a topical composition, e.g., a physically and chemically stable topical composition of Fenoldopam comprising about 0.1% to about 5% by weight of Fenoldopam or a pharmaceutically acceptable salt thereof, at least one polyacrylamide-type gelling agent, at least one cellulose-type gelling agent, and at least one solvent, wherein the Fenoldopam is substantially solubilized in the composition, and wherein the composition is stable for at least twelve months at 25° C. and 60% relative humidity.
Utility
Topical Montelukast Formulations
20 Jan 22
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Utility
Topical Montelukast Formulations
23 Dec 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Utility
Topical Montelukast formulations
16 Nov 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.
Utility
Topical Montelukast Formulations
5 Aug 21
The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5.